Notícias e Atividades da Eagle Pharmaceuticals

Eagle Pharmaceuticals é uma empresa listada sob o símbolo EGRX (US).

Veja o organograma con seus 30 executivos principais

Biografias mais buscadas da Eagle Pharmaceuticals

• Michael Graves, Interim Executive Chairman of the Board
• Jennifer Simpson, Director
• Robert Glenning, Director

Recentes movimentos de executivos em Eagle Pharmaceuticals

• Debra Hussain, Head of Commercial, Acute Care and Hospital, deixou a Companhia  (Notícia publicada em 13 de maio de 2026).

Criar um alerta
para seguir os movimentos de executivos da Eagle Pharmaceuticals.

Eagle Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Eagle Pharmaceuticals

• Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection) | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke | Eagle Pharmaceuticals Investor Center
• Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• View more press releases Close

Redes sociais sobre Eagle Pharmaceuticals

• Eagle Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Eagle Pharmaceuticals na LinkedIn, X (Twitter) e YouTube